NCT02556892View on ClinicalTrials.gov

A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 3, 2015

Primary Completion Date

August 20, 2018

Study Completion Date

August 20, 2018

Conditions

Lymphocytic Leukemia

Interventions

DRUG

Ibrutinib

Participants will self-administer 420 milligram (mg) oral ibrutinib once daily continuously from Cycle 1 to Cycle 6 and thereafter every 28 days until treatment discontinuation.

Trial Locations (8)

Unknown

Fukuoka

Hiroshima

Isehara

Kobe

Kōtoku

Osaka

Sapporo

Tachikawa